Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis.
- Author:
Jiu-gen LIANG
1
;
Ning-yi JIANG
;
Jian-qiang DU
;
Xian-ping LU
;
Xing-guang LIU
;
Shao-xiong CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Agents; therapeutic use; Bone Neoplasms; complications; secondary; therapy; Breast Neoplasms; drug therapy; pathology; radiotherapy; Carcinoembryonic Antigen; blood; Combined Modality Therapy; Diphosphonates; therapeutic use; Etidronic Acid; therapeutic use; Female; Follow-Up Studies; Humans; Middle Aged; Organometallic Compounds; therapeutic use; Pain; etiology; Pain Management; Radioisotopes; therapeutic use; Rhenium; therapeutic use
- From: Chinese Journal of Oncology 2005;27(3):180-182
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis.
METHODSForty-eight patients with breast cancer with multi-bone metastases were randomly divided into three groups:15 patients received (188)Re-HEDP (group A), 15 patients received pamidronate (group B) and 18 patients were treated by (188)Re-HEDP plus pamidronate (group C).
RESULTSThe overall pain relief rate was 73.3%, 80.0%, 100.0% in groups A, B and C. The response rate of bone metastasis was 40.0%, 33.3%, 66.7% in groups A, B and C respectively. The therapeutic effect of group C was better than those of groups A and B (P < 0.05), without any significance in the difference (P > 0.05).
CONCLUSIONThe therapeutic effect of (188)Re-HEDP combined with pamidronate for breast cancer with bone metastasis is remarkable in bone pain relief and bone metastasis control, which is better than either (188)Re-HEDP or pamidronate alone.
